Citations - Colombo Nicoletta

CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Colombo Nicoletta
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Colombo Nicoletta
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Colombo Nicoletta
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Colombo Nicoletta
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Colombo Nicoletta
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Colombo Nicoletta
By: M R Mirza
  • Other

    Citations

  • Other

    Citations

Translate »